NASDAQ:PSTX

Poseida Therapeutics Competitors

$8.62
-0.28 (-3.15 %)
(As of 04/16/2021 11:05 AM ET)
Add
Compare
Today's Range
$8.57
Now: $8.62
$8.71
50-Day Range
$8.50
MA: $9.93
$11.91
52-Week Range
$7.63
Now: $8.62
$17.62
Volume1,776 shs
Average Volume404,020 shs
Market Capitalization$535.37 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Poseida Therapeutics (NASDAQ:PSTX) Vs. SRNE, BCRX, BLUE, RUBY, NK, and KYMR

Should you be buying PSTX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Poseida Therapeutics, including Sorrento Therapeutics (SRNE), BioCryst Pharmaceuticals (BCRX), bluebird bio (BLUE), Rubius Therapeutics (RUBY), NantKwest (NK), and Kymera Therapeutics (KYMR).

Poseida Therapeutics (NASDAQ:PSTX) and Sorrento Therapeutics (NASDAQ:SRNE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Analyst Recommendations

This is a summary of recent recommendations for Poseida Therapeutics and Sorrento Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Poseida Therapeutics00303.00
Sorrento Therapeutics00403.00

Poseida Therapeutics presently has a consensus price target of $25.00, indicating a potential upside of 190.02%. Sorrento Therapeutics has a consensus price target of $28.75, indicating a potential upside of 290.63%. Given Sorrento Therapeutics' higher probable upside, analysts plainly believe Sorrento Therapeutics is more favorable than Poseida Therapeutics.

Profitability

This table compares Poseida Therapeutics and Sorrento Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Poseida TherapeuticsN/AN/AN/A
Sorrento Therapeutics-698.01%-314.06%-43.60%

Institutional & Insider Ownership

41.1% of Poseida Therapeutics shares are held by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are held by institutional investors. 19.0% of Poseida Therapeutics shares are held by insiders. Comparatively, 3.4% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Poseida Therapeutics and Sorrento Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poseida TherapeuticsN/AN/AN/A($6.86)-1.26
Sorrento Therapeutics$31.43 million65.77$-292,070,000.00($2.12)-3.47

Poseida Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Poseida Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Poseida Therapeutics beats Sorrento Therapeutics on 6 of the 10 factors compared between the two stocks.

Poseida Therapeutics (NASDAQ:PSTX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Institutional & Insider Ownership

41.1% of Poseida Therapeutics shares are held by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are held by institutional investors. 19.0% of Poseida Therapeutics shares are held by insiders. Comparatively, 4.3% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Poseida Therapeutics and BioCryst Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Poseida Therapeutics00303.00
BioCryst Pharmaceuticals03802.73

Poseida Therapeutics presently has a consensus price target of $25.00, indicating a potential upside of 190.02%. BioCryst Pharmaceuticals has a consensus price target of $12.3333, indicating a potential upside of 10.51%. Given Poseida Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Poseida Therapeutics is more favorable than BioCryst Pharmaceuticals.

Profitability

This table compares Poseida Therapeutics and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Poseida TherapeuticsN/AN/AN/A
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%

Valuation and Earnings

This table compares Poseida Therapeutics and BioCryst Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poseida TherapeuticsN/AN/AN/A($6.86)-1.26
BioCryst Pharmaceuticals$48.83 million40.57$-108,900,000.00($0.94)-11.87

Poseida Therapeutics has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Poseida Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Poseida Therapeutics beats BioCryst Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Poseida Therapeutics (NASDAQ:PSTX) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Institutional & Insider Ownership

41.1% of Poseida Therapeutics shares are held by institutional investors. Comparatively, 94.3% of bluebird bio shares are held by institutional investors. 19.0% of Poseida Therapeutics shares are held by company insiders. Comparatively, 3.6% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Poseida Therapeutics and bluebird bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Poseida Therapeutics00303.00
bluebird bio012602.33

Poseida Therapeutics presently has a consensus target price of $25.00, indicating a potential upside of 190.02%. bluebird bio has a consensus target price of $61.40, indicating a potential upside of 112.16%. Given Poseida Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Poseida Therapeutics is more favorable than bluebird bio.

Profitability

This table compares Poseida Therapeutics and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Poseida TherapeuticsN/AN/AN/A
bluebird bio-256.84%-45.78%-35.14%

Earnings and Valuation

This table compares Poseida Therapeutics and bluebird bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poseida TherapeuticsN/AN/AN/A($6.86)-1.26
bluebird bio$44.67 million43.50$-789,610,000.00($14.31)-2.02

Poseida Therapeutics has higher earnings, but lower revenue than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Poseida Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Poseida Therapeutics beats bluebird bio on 8 of the 11 factors compared between the two stocks.

Poseida Therapeutics (NASDAQ:PSTX) and Rubius Therapeutics (NASDAQ:RUBY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Institutional & Insider Ownership

41.1% of Poseida Therapeutics shares are held by institutional investors. Comparatively, 93.7% of Rubius Therapeutics shares are held by institutional investors. 19.0% of Poseida Therapeutics shares are held by company insiders. Comparatively, 58.4% of Rubius Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Poseida Therapeutics and Rubius Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Poseida Therapeutics00303.00
Rubius Therapeutics03102.25

Poseida Therapeutics presently has a consensus target price of $25.00, indicating a potential upside of 190.02%. Rubius Therapeutics has a consensus target price of $23.3333, indicating a potential downside of 2.17%. Given Poseida Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Poseida Therapeutics is more favorable than Rubius Therapeutics.

Profitability

This table compares Poseida Therapeutics and Rubius Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Poseida TherapeuticsN/AN/AN/A
Rubius TherapeuticsN/A-77.33%-49.05%

Earnings and Valuation

This table compares Poseida Therapeutics and Rubius Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poseida TherapeuticsN/AN/AN/A($6.86)-1.26
Rubius TherapeuticsN/AN/A$-163,460,000.00($2.08)-11.47

Rubius Therapeutics is trading at a lower price-to-earnings ratio than Poseida Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Poseida Therapeutics beats Rubius Therapeutics on 6 of the 9 factors compared between the two stocks.

Poseida Therapeutics (NASDAQ:PSTX) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Earnings and Valuation

This table compares Poseida Therapeutics and NantKwest's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poseida TherapeuticsN/AN/AN/A($6.86)-1.26
NantKwest$40,000.0047,182.37$-65,790,000.00($0.70)-24.66

Poseida Therapeutics has higher earnings, but lower revenue than NantKwest. NantKwest is trading at a lower price-to-earnings ratio than Poseida Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Poseida Therapeutics and NantKwest's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Poseida TherapeuticsN/AN/AN/A
NantKwest-76,658.58%-56.06%-46.93%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Poseida Therapeutics and NantKwest, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Poseida Therapeutics00303.00
NantKwest00103.00

Poseida Therapeutics presently has a consensus target price of $25.00, indicating a potential upside of 190.02%. NantKwest has a consensus target price of $18.00, indicating a potential upside of 4.29%. Given Poseida Therapeutics' higher probable upside, analysts plainly believe Poseida Therapeutics is more favorable than NantKwest.

Institutional & Insider Ownership

41.1% of Poseida Therapeutics shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 19.0% of Poseida Therapeutics shares are held by company insiders. Comparatively, 71.7% of NantKwest shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Poseida Therapeutics beats NantKwest on 7 of the 10 factors compared between the two stocks.

Kymera Therapeutics (NASDAQ:KYMR) and Poseida Therapeutics (NASDAQ:PSTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Analyst Ratings

This is a breakdown of current ratings and target prices for Kymera Therapeutics and Poseida Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kymera Therapeutics02502.71
Poseida Therapeutics00303.00

Kymera Therapeutics currently has a consensus target price of $48.6667, indicating a potential upside of 26.41%. Poseida Therapeutics has a consensus target price of $25.00, indicating a potential upside of 190.02%. Given Poseida Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Poseida Therapeutics is more favorable than Kymera Therapeutics.

Institutional and Insider Ownership

37.8% of Kymera Therapeutics shares are held by institutional investors. Comparatively, 41.1% of Poseida Therapeutics shares are held by institutional investors. 19.0% of Poseida Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Kymera Therapeutics and Poseida Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera TherapeuticsN/AN/AN/AN/AN/A
Poseida TherapeuticsN/AN/AN/A($6.86)-1.26

Profitability

This table compares Kymera Therapeutics and Poseida Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kymera TherapeuticsN/AN/AN/A
Poseida TherapeuticsN/AN/AN/A

Summary

Poseida Therapeutics beats Kymera Therapeutics on 4 of the 5 factors compared between the two stocks.


Poseida Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.36-1.1%$2.09 billion$31.43 million-5.04Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.16-1.6%$2.01 billion$48.83 million-14.68Analyst Report
bluebird bio logo
BLUE
bluebird bio
1.8$28.94-2.7%$2.00 billion$44.67 million-2.64
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.85-0.8%$1.95 billionN/A-11.14Decrease in Short Interest
Gap Up
NantKwest logo
NK
NantKwest
1.1$17.26-4.7%$1.89 billion$40,000.00-24.31
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.50-0.2%$1.73 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$76.36-0.3%$1.70 billionN/A-51.59
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.39-3.3%$1.69 billion$102.43 million-18.98
Immunovant logo
IMVT
Immunovant
1.8$15.58-1.9%$1.56 billionN/A-12.08Increase in Short Interest
News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.38-4.3%$1.52 billion$35.23 million-13.86Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$18.93-4.0%$1.48 billion$7.80 million-17.69
AlloVir logo
ALVR
AlloVir
1.4$22.18-1.9%$1.47 billionN/A0.00Increase in Short Interest
Alector logo
ALEC
Alector
1.3$18.48-4.9%$1.47 billion$21.22 million-8.29
Replimune Group logo
REPL
Replimune Group
1.5$30.23-2.8%$1.45 billionN/A-17.08
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.08-2.6%$1.42 billionN/A0.00Increase in Short Interest
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$26.55-6.7%$1.34 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.89-1.2%$1.17 billion$32.16 million-10.10Analyst Upgrade
Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.24-5.3%$1.17 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.89-4.4%$1.16 billionN/A-3.98Increase in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$39.50-2.1%$1.14 billionN/A-16.46Analyst Downgrade
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.78-0.4%$1.06 billion$20.49 million-12.77Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.34-0.7%$1.04 billion$356.07 million7.03
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.41-5.9%$1.00 billionN/A0.00Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.00-6.8%$979.79 million$42.74 million-222.22Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$24.53-1.5%$940.63 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Passage Bio logo
PASG
Passage Bio
1.8$16.16-6.4%$925.89 millionN/A0.00Increase in Short Interest
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.77-7.2%$919.28 million$250,000.00-6.91Analyst Upgrade
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.01-0.8%$911.40 millionN/A-4.13Insider Selling
Increase in Short Interest
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.17-1.9%$904.23 millionN/A-9.99Increase in Short Interest
Analyst Revision
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.71-2.7%$850.59 millionN/A0.00Lockup Expiration
Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.68-1.4%$840.75 million$69.89 million-4.22
Cellectis logo
CLLS
Cellectis
1.3$19.13-0.9%$825.65 million$22.99 million-10.18
Inhibrx logo
INBX
Inhibrx
1.6$19.89-5.5%$791.95 millionN/A0.00Decrease in Short Interest
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.15-3.1%$784.23 million$2.51 million-3.73
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.89-3.1%$783.55 million$1.12 million-4.94Increase in Short Interest
Gap Up
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.11-2.3%$686.71 million$14.75 million-2.62Increase in Short Interest
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$19.90-1.8%$656.65 million$5.78 million-9.34Insider Selling
Unusual Options Activity
Analyst Revision
Vaxart logo
VXRT
Vaxart
1.3$5.23-3.8%$638.89 million$9.86 million-8.86
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.36-0.3%$633.42 million$13.29 million-10.18
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$28.12-8.9%$628.01 millionN/A0.00Lockup Expiration
Gap Down
Athira Pharma logo
ATHA
Athira Pharma
2.1$16.63-1.1%$610.62 millionN/A0.00Analyst Downgrade
Compugen logo
CGEN
Compugen
1.4$8.46-5.2%$608.94 million$17.80 million-22.86Analyst Report
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.73-3.0%$553.18 millionN/A-5.97Gap Up
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.00-3.4%$552.56 millionN/A-2.43Increase in Short Interest
Agenus logo
AGEN
Agenus
1.6$2.59-2.7%$544.46 million$150.05 million-2.38
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.59-4.1%$510.85 million$22.24 million-4.27Increase in Short Interest
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.21-5.2%$486.84 millionN/A-8.14Increase in Short Interest
AVROBIO logo
AVRO
AVROBIO
1.7$10.87-5.8%$478.65 millionN/A-3.29News Coverage
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.25-5.0%$440.78 million$147.87 million-3.07
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.